Molsidomine increases endotoxic survival and decreases cytokine production

Shock

Volumn 7, Issue 3, 1997, Pages 200-205

  Kumins, Norman H ^b   Hunt, Julia ^a   Gamelli, Richard L ^a   Filkins, James P ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ENDOTOXIN; INTERLEUKIN 1; INTERLEUKIN 6; MOLSIDOMINE; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; LIVER; LIVER DISEASE; MALE; METABOLISM; MOUSE; MOUSE STRAIN; PATHOPHYSIOLOGY; PHYSIOLOGY; SEPTIC SHOCK; SURVIVAL;

ANIMALS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTOXINS; INTERLEUKIN-1; INTERLEUKIN-6; LIVER; LIVER DISEASES; MALE; MICE; MICE, INBRED STRAINS; MOLSIDOMINE; NITRIC OXIDE; SHOCK, SEPTIC; SURVIVAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031092105     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199703000-00008     Document Type: Article

References (28)

1. Center for Disease Control: Increase in national hospital discharge survey rates for septicemia - United States: 1979-1987. MMWR 39:31-34, 1990.
2. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled trial of high-dose methylprednisone in the treatment of severe sepsis and septic shock. N Engl J Med 317:653-658, 1987.
3. Parrillo JE: Pathogenetic mechanisms of septic shock. N Engl J Med 328:1471-1477, 1993.
4. Waage A, Shalaby R, Espivik T: Tumor necrosis factor, interleukin-1, interleukin-6, interleukin-8, and interferon gamma in septic shock. In Kunkel SL, Remick DH (eds): Cytokines in Health and Disease. New York: Marcel Dekker, Inc., 1992, pp 151-164.
5. Nussler AK, Billiar TR: Inflammation, immunoregulation and inducible nitric oxide synthase. J Leukocyte Biol 54:171-178, 1993.
6. Kilbourn RG, Griffith OW. Overproduction of nitric oxide in cytokine-mediated and septic shock. J Natl Cancer Inst 84:827-831, 1992.
7. Furchgott RF: Vasodilation. In Vanhoutte P (ed): Vascular Smooth Muscle, Peptides, Autonomic Nerves, and Endothelium. New York: Raven Press, 1988, 401-414.
8. Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109-142, 1991.
9. Wolfe TA, Dasta JF. Use of nitric oxide synthase inhibitors as a novel treatment for septic shock. Ann Pharmacother 29:36-46, 1995.
10. Fulle HJ, Endres S, Sinha B, Stoll D, Weber P, Gerzer R: Effects of SIN-1 on cytokine synthesis in human mononuclear cells. J Cardiovas Pharmacol 17(suppl 3):S113-S116, 1991.
11. Eigler A, Sinha B, Endres S: Nitric oxide-releasing agents enhance cytokine-induced tumor necrosis factor synthesis in human mononuclear cells. Biochem Biophys Res Commun 196:494-501, 1993.
12. Kumins NH, Hunt J, Gamelli RL, Filkins JP. Partial hepatectomy reduces the endotoxin induced peak circulating level of tumor necrosis factor in rats. Shock 5:385-388, 1996.
13. Kumins NH, Hunt J, Gamelli RL, Filkins JP: The perfused mouse liver produces TNF, IL-1 and IL-6 after endotoxin. Surg Forum 45:59-62, 1994.
14. Zingarelli B, Halushka PV, Caputi AP, Cook JA: Increased nitric oxide synthesis during the development of endotoxin tolerance. Shock 3:102-108, 1995.
15. Assimacopoulos-Jeannet F, Exton JH, Jeanrenaud B: Control of gluconeogenesis and glycogenolysis in perfused livers of normal mice. Am J Physiol 225:25-32, 1973.
16. Billiar TR, Huffman RA, Curran RD, Langrehe JM, Simmons RL: A role for inducible nitric oxide biosynthesis in the liver in inflammation and in the allogeneic immune response. J Lab Clin Med 120:192-197, 1992.
17. Palmer RM: The discovery of nitric oxide in the vessle wall, a unifying concept in the pathogenesis of sepsis. Arch Surg 28:396-401, 1993.
18. Bassenge E, Mulsch A: Anti-ischemic actions of molsidomine by venous and large coronary dilation in combination with anti-platelet effects. J Cardiovasc Pharmacol 14:S23-S28, 1989.
19. Carey C, Siegfried MR, Ma XL, Weyrich AS, Lefer AM: Antishock and endothelial protective actions of a NO donor in mesenteric ischemia and reperfusion. Circ Shock 38:209-216, 1992.
20. Christopher TA, MA XL, Lefer AM. Beneficial actions of S-nitroso-N-acetyl-penicillamine, a nitric oxide donor in murine traumatic shock. Shock 1:19-24, 1992.
21. Symington PA, Ma XL, Lefer AM. Protective actions of S-nitroso-N-acetyl-penicillamine (SNAP) in a rat model of hemorrhagic shock. Methods Find Exp Clin Pharmacol 14:789-797, 1992.
22. Boughton-Smith NK, Hutcheson IR, Deakin AM, Whittle BJ, Moncada S: Protective effects of S-nitroso-N-acetyl-penicillamine in endotoxin-induced acute intestinal damage in the rat. Eur J Pharmacol 191:485-488, 1990.
23. Hutcheson AR, Whittle BJR, Boughton-Smith NK: Role of nitric oxide in maintaining vascular integrity in endotoxin-induced acute intestinal damage in the rat. Br J Pharmacol 101:815-820, 1990.
24. Wink DA, Hanbauer I, Krishna MC, DeGraff W, Gamson J, Mitchell JB: Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc Natl Acad Sci USA 90:9813-9817, 1993.
25. Harbrecht BG, Billiar TR, Stadier J, et al: Inhibiting nitric oxide synthesis during endotoxemia promotes intrahepatic thrombosis and oxygen radical-mediated hepatic injury. J Leukocyte Biol 52:390-394, 1992.
26. O'Neil S, Hunt J, Gamelli R, Filkins JP. A comparison of the effects of nitric oxide (NO) a synthesis inhibition vs NO donation on hepatic TNF production in endotoxicosis. Shock 5(suppl):62, 1996.
27. Tanayama S, Nakai Y, Fujita T, Suzouki Z: Biotransformation of molsidomine (N-ethoxycarbonyl-morpholinsosydnonimine), a new anti-anginal agent in rats. Xenobiotica 4:175-191, 1974.
28. Rosenkranz B, Winkelman BR, Parnham MT: Clinical pharmacokinetics of molsidomine. Clin Pharmacokinet 5:372-384, 1996.